Company: LASR
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001124796-25-000043
Chunk: 65

Company: NLIGHT, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 65
---
 so that Mr. Corso will be eligible to receive the vesting acceleration benefits described below to the extent applicable.

In addition, pursuant to the employment agreement with Mr. Corso, if, within the period beginning three months prior to and ending 12 months following a “change in control” (as defined in Mr. Corso's employment agreement) (such period referred to as the “change in control period”), the employment of Mr. Corso is terminated other than for death, “disability,” or “cause” or Mr. Corso resigns for “good reason” and Mr. Corso executes a waiver and release of claims in our favor that becomes effective and irrevocable within 60 days following his termination, Mr. Corso will be entitled to (i) a lump sum payment equal to 12 months of his base salary, (ii) premium payments to maintain group health insurance continuation benefits pursuant to “COBRA” for him and his respective dependents for up to 12 months, or taxable monthly payments of an equivalent amount for the same period, and (iii) 100% of the then-unvested shares subject to his outstanding equity awards will immediately become vested and exercisable (in the case of equity awards with performance-

<div align='center'>49</div>

based vesting, all performance goals and other vesting criteria will be deemed achieved at the greater of actual performance measured as of the date of termination or 100% of target levels, unless the applicable equity award agreement provides otherwise).

Mr. Corso’s employment agreement includes a Section 280G “best results” provision as described above for Mr. Keeney.

Potential Payments upon Termination or Change-In-Control

The following tables provide information concerning the estimated payments and benefits that would be provided in the circumstances described above, assuming that the triggering event took place on December 31, 2024, the last day of our fiscal year. For purposes of valuing accelerated vesting, the values indicated in the tables below are calculated, with respect to RSAs or RSUs, as $10.49 (the closing price of a share of our common stock on December 29, 2024, the last trading day of 2024), multiplied by the number of unvested shares subject to the RSAs or RSUs as of December 31, 2024 that are being accelerated (and for performance-based RSAs or RSUs, based on the target number of shares). Neither Mr. Keeney